We stably transfected human embryonic kidney cells (HEK 293 cells) with genes encoding rat neuronal nicotinic receptor ␣2, ␣3, or ␣4 subunits in combination with the ␤2 or ␤4 subunit to generate six cell lines that express defined subunit combinations that represent potential subtypes of rat neuronal nicotinic acetylcholine receptors (nAChRs). These cell lines were designated KX␣2␤2, KX␣2␤4, KX␣3␤2, KX␣3␤4, KX␣4␤2, and
subtypes containing the ␤2 subunit compared with those containing the ␤4 subunit. An excellent correlation (r Ͼ 0.99) of the binding affinities of the 10 agonists was observed between receptors from KX␣4␤2 cells and from rat forebrain tissue, in which [
3 H]EB binding represents predominantly ␣4␤2 nAChRs. More important, the affinities (K i values) for the two tissues were nearly identical. The densities of the binding sites of all six cell lines were increased after a 5-day exposure to (Ϫ)-nicotine or the quaternary amine agonist carbachol. These data indicate that these cell lines expressing nAChR subunit combinations should be useful models for investigating pharmacological properties and regulation of the binding sites of potential nAChR subtypes, as well as for studying the properties of nicotinic compounds.
Neuronal nicotinic acetylcholine receptors (nAChRs) are found throughout the CNS and peripheral nervous system. In the CNS, they are located on neuronal cell bodies and dendrites, where they mediate fast excitatory postsynaptic responses to acetylcholine and other nicotinic agonists, as well as on axon terminals or preterminal sites. These receptors are often found associated with dopamine, norepinephrine, GABA, acetylcholine, and glutamate neurons, where they can mediate the influence of acetylcholine and other nicotinic agonists on the firing of these neurons and the release of their transmitters. In the peripheral nervous system, nAChRs mediate excitatory neurotransmission at virtually all autonomic ganglia, the adrenal gland, and at sensory ganglia; therefore, they are critical for the normal function and adaptation of nearly all organ systems. In addition, these receptors are found in the pineal gland (Marks et al., 1998; Hernandez et al., 1999; Perry et al., 2002) , where they may influence melatonin secretion (Yamada et al., 1998) , vascular endothelial and bronchial epithelial cells Maus et al., 1998) , and skin keratinocytes (Grando et al., 1995) , where their functions are not yet known.
nAChRs are composed of ␣ and ␤ subunits that form pentameric ligand-gated cation channels. Nine ␣ subunits (␣2-␣10) and three ␤ subunits (␤2-␤ 4) have been identified in vertebrate neuronal tissues, and different combinations of these subunits define nAChR subtypes. The rules of subunit assembly are not yet well established; therefore, it is not known how many subtypes actually exist. Receptors composed of ␣4 and ␤2 subunits (the ␣4␤2 subtype) and those containing ␣7 subunits (the ␣7* subtype) appear to represent the largest number of nAChRs in the CNS, but receptors containing ␣2, ␣3, ␣6, ␤3, and ␤4 subunits are also found in specific CNS nuclei and regions and very likely serve important physiological functions. In autonomic and sensory ganglia and in the adrenal gland, nAChRs containing ␣3 subunits in association with ␤2 or ␤4 subunits appear to predominate.
All of the nAChRs receptors conduct Na ϩ , K ϩ , and Ca 2ϩ when activated; however, the different receptor subtypes have distinguishing pharmacological and/or functional properties, including binding affinities of ligands, efficacies and potencies of agonists and antagonists, channel conductances, and rates of desensitization and recovery (Lindstrom et al., 1996; Albuquerque et al., 1997; Colquhoun and Patrick, 1997) . Because most neuronal tissues express mRNA for multiple nAChR subunits and therefore have the potential to express more than one subtype of receptor, it is not possible to precisely compare the pharmacological properties across a broad range of receptor subtypes in native tissues. Expression of putative nAChR subtypes in Xenopus laevis oocytes has allowed some systematic studies of the pharmacology of nAChR function (Chavez-Noriega et al., 1997) and binding sites (Parker et al., 1998) across subtypes. Similarly, the pharmacological properties of nAChR subtypes stably expressed in mouse fibroblasts (Whiting et al., 1991) , human embryonic kidney (HEK 293) cells (Gopalakrishnan et al., 1996; Stauderman et al., 1998; Wang et al., 1998; Xiao et al., 1998; Jensen et al., 2003) , and human epithelial (SH-EP1) cells (Eaton et al., 2003) have been studied in some detail. Studies that compared the pharmacology of the subtypes have found that the potencies and affinities of any one drug can vary considerably across the subtypes. Here, we extend that type of study by systematically comparing the binding affinities of 12 commonly used nicotinic drugs at six putative nAChR subtypes stably expressed in mammalian cells. We chose HEK 293 cells as the host for stably expressing rat nAChR genes because of their relatively high transfection efficiency, ease of culturing, and good adhesion to plastic or glass surfaces. In addition, since there have been several human nAChR subtypes stably expressed in this cell line, it will eventually be possible to compare rat and human receptors expressed in the same cell line. The data presented here can serve as reference points for further systematic comparisons of drugs across nAChR subtypes.
Exposure to nicotine increases the number of nAChRs in rodent and human brain in vivo (Marks et al., 1983; Schwartz and Kellar, 1983; Benwell et al., 1988; Breese et al., 1997; Perry et al., 1999) and in mammalian cell lines that express native (Peng et al., 1997; Avila et al., 2003) or heterologous (Peng et al., 1994; Wang et al., 1998; Meyer et al., 2001) nAChRs. To determine whether this increase reflects a generalized property of nAChRs, we measured the effects of a 5-day exposure to nicotine on the number of nAChR binding sites for each of the six nAChR subtypes examined here. In addition, to determine whether the increase in receptors is likely initiated by an action at the cell surface, the effects of exposure to carbachol, a quaternary amine nicotinic agonist that does not readily enter cells, was also measured. Expression Constructs. Five plasmids that carry the cDNA clones of rat neuronal nAChR subunit ␣2, ␣3, ␣4, ␤2, and ␤4 genes (pHYP16-9, pPCA48E-3, pHYA23-1E-1, pPCX49-1, and pZPC13, respectively) and have been previously described (Boulter et al., 1987; Duvoisin et al., 1989) were generously provided by Dr. J. Boulter (University of California, Los Angeles). To constitutively express these rat neuronal nAChR subunits in mammalian cells, cDNA fragments containing entire coding sequences of the subunit genes were subcloned into the eukaryotic expression vector pcDNA3 (Invitrogen). The resulting expression constructs with the ␣2, ␣3, ␣4, ␤2, and ␤4 subunit genes were designated pKX␣2RC1, pKX␣3RC1, pKX␣4RC1, pKX␤2RC1, and pKX␤4RC1, respectively.
Materials and Methods

Materials and
Cell Culture and Stable Transfection. HEK 293 cells (CRL 1573; American Type Culture Collection, Manassas, VA) were maintained at 37°C with 5% CO 2 in a humidified incubator. Growth medium for the HEK 293 cells was minimum essential medium supplemented with 10% fetal bovine serum, 100 unit/ml penicillin G, and 100 g/ml streptomycin. Transfection of HEK 293 cells, selection, and establishment of stable cell lines were carried out as described previously (Xiao et al., 1998) . Stably transfected cell lines were grown in selection growth medium containing 0.7 mg/ml Geneticin (G418). After selection, six stable cell lines engineered to express combinations of an ␣ subunit gene and one of the ␤ subunit genes, were designated KX␣2␤2, KX␣2␤4, KX␣3␤2, KX␣3␤4R2, KX␣4␤2, and KX␣4␤4. The expression pattern of each cell line was confirmed using multiple probe RNase protection assays as described previously (Xiao et al., 1998) . In studies where cells were grown in the presence of nicotine hydrogen tartrate (nicotine) or carbamylcholine chloride (carbachol), these drugs were added to the selection growth medium on day 1 of a 5-day growth period.
Radioligand Binding Assay. Binding of [ 3 H]EB to nAChRs was measured as described previously (Xiao et al., 1998) , with minor modifications. In brief, cultured cells at Ͼ80% confluence were removed from their flasks (80 cm 2 ) with a disposable cell scraper and placed in 10 ml of 50 mM Tris⅐HCl buffer (pH 7.4, 4°C). The cell suspension was centrifuged at 1000g for 5 min, and the pellet was collected. For cells treated chronically with nicotinic agonists during culturing, the pellet was washed two more times by centrifugation in fresh buffer to remove residual drug. The cell pellet was then homogenized in 10 ml of buffer with a Brinkmann polytron homogenizer (setting 6, 20 s) and centrifuged at 36,000g for 10 min at 4°C. The membrane pellet was resuspended in fresh buffer, and aliquots of the membrane preparation equivalent to 30 to 200 g of protein were used for binding assays. Membrane preparations were incubated with [ 3 H]EB for 4 h at 24°C. The volumes for saturation and competition binding assays were 1 and 0.5 ml/tube, respectively. Nonspecific binding was assessed in parallel incubations in the presence of 300 M nicotine. Bound and free ligands were separated by vacuum filtration through Whatman GF/C filters treated with 0.5% polyethylenimine. The filter-retained radioactivity was measured by liquid scintillation counting. Specific binding was defined as the difference between total binding and nonspecific binding. Data from saturation and competition binding assays were analyzed using
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Prism 3 (GraphPad Software Inc., San Diego, CA). Additional statistical analyses are indicated in the figure legends.
Results
Binding of [ 3 H]EB to nAChR Subtypes Stably Expressed in HEK 293 Cells. Specific binding of [
3 H]EB was found in membranes from cells expressing each of the ␣/␤ subunit combinations examined (see below); whereas, in contrast, binding was not detected in the parent HEK cells, HEK cells transfected with the pcDNA3 vector, or cells expressing any of the ␣ or ␤ subunits alone (Xiao et al., 1998 ; data not shown). The binding of [ 3 H]EB over a concentration range of 1 to 3500 pM was examined in cells expressing each of the nAChR subtypes, as defined by their subunit combination. In each case, [
3 H]EB specific binding was saturable and fit best to a model for a single high-affinity site ( Fig. 1 (Whiting and Lindstrom, 1987; Flores et al., 1992) . Similarly, the K d value at the heterologously expressed ␣3␤4 subtype matches well with the value found in rat pineal gland, which appears to 3 H]EB concentration range of ϳ1 to 3000 pM. Binding data were analyzed by nonlinear least square regressions using Prism 3 software. The data were fit to both one-and two-site saturation binding models. The data from these six cell lines fit best to the one-site model in all cases. Data shown are from a single representative experiment. See Table 1 for a summary of data from all experiments. express this subtype nearly exclusively (Hernandez et al., 1999; Perry et al., 2002) .
The density of the nAChR binding sites in these cells ranged from ϳ64 to Ͼ9,000 fmol/mg protein, and for most subtypes examined here, the density of sites was Ͼ300 fmol/mg protein ( (Harvey et al., 1996) , was a weaker competitor than most agonists at these receptors (Fig. 2) .
Because the affinity of [ 3 H]EB at the different subtypes examined here varies by up to 14-fold (Table 1) , and the binding competition assays were carried out using ϳ500 pM [ 3 H]EB for all of the nAChR subtypes, the IC 50 values taken directly from the competition curves do not readily reflect the relative affinity of a ligand across the different receptor subtypes. Therefore, the K i values, calculated from the IC 50 values (Cheng and Prusoff, 1973) , of these 12 nicotinic ligands at the six heterologously expressed receptor subtypes and in rat forebrain are provided in Table 2 . Epibatidine and its iodinated analog had the highest affinities across all of the receptor subtypes and were also the least discriminating of the ligands at these subtypes. In general, the ligands examined had higher affinities for receptor subtypes containing the ␤2 subunit than for those containing the ␤4 subunit. It is also evident from Table 2 that, in general, the agonists had lower affinity for receptor subtypes containing the ␣3 subunit than for those containing ␣2 or ␣4 subunits. Thus, the affinity of every agonist ligand examined here except DMPP was lowest at the ␣3␤4 subtype (Table 2) .
More specifically, as was seen with the binding of [ 3 H]EB, the affinity of nearly every ligand examined was higher at the receptor subtype formed by the combination of any of the ␣ subunits with the ␤2 subunit than with the ␤4 subunit. The binding affinity ratio for a ligand, calculated from its affinities at an ␣ subunit paired with the ␤2 subunit versus the ␤4 subunit, represents a measure of selectivity of that ligand with regard to the ␤ subunits. Table 3 summarizes these ratios for the 12 ligands examined here. In some cases, any difference in affinity was too small to measure, yielding ratios close to 1; for example, iodo-epibatidine and cytisine at ␣4␤2 and ␣4␤4 receptors. However, in other cases, the differences were relatively large; for example, the affinities of acetylcholine and nicotine were 9 to 15 times higher at ␣2␤2 and ␣3␤2 subtypes than at the corresponding ␤4 subtypes. The largest differences in affinities between the receptor subtypes containing ␤2 versus ␤4 subunits were seen with A-85380, which displayed affinity ratios of 58 to 370, and I-A-85380, which displayed ratios of 410 to 1300 and was the most selective ligand examined here. The one exception to this rule among the ligands examined was the antagonist MLA, which has higher affinity for ␣4␤4 than ␣4␤2 receptors (Table 3) . MLA has high affinity for ␣7 nAChRs (ϳ1 nM), where it is a relatively selective competitive antagonist (Ward et al., 1990; Davies et al., 1999) . In contrast, its affinities at the six heteromeric receptors examined here are much lower, and even its highest affinities (1-2 M), which are seen at the two receptor subtypes containing ␣3 subunits (Table 2) , are 1000 times lower than at the ␣7 subtype. The competitive antagonist DH␤E has its highest affinity at the ␣4␤2 subtype and is at least 6-fold selective for this subtype compared with the other subtypes examined (Table 2) . Mecamylamine, a noncompetitive nAChR antagonist that blocks the receptor channel, did not compete effectively for the [ 3 H]EB binding site at any of the receptor subtypes at concentrations below 500 M (Table 2) .
We also compared the affinity ratios of these ligands at ␣3␤4 receptors, which mediate much of the cholinergic signaling in peripheral ganglia and at the ␣4␤2 receptors in rat forebrain (Table 3 ). The two A-85380 compounds had high affinity ratios, with I-A-85380 being the most selective between these two receptor subtypes, displaying a ratio of ϳ2500. Cytisine and DH␤E also showed high selectivity (affinity ratios of ϳ120 and 850, respectively) for the receptors in forebrain compared with the ␣3␤4 subtype ( Table 3) .
The utility of a cell line that expresses a nAChR subtype defined by its heterologous receptor subunits depends on how well that receptor reflects the pharmacology of native nAChR binding sites, thereby allowing them to serve as models of these receptors for at least some purposes. There are very few native tissues that express only a single subtype of nAChR of known subunit composition, which would allow the pharmacology of these cell lines to be compared. The rat forebrain comes close to fulfilling these criteria, since most (ϳ90%) of the nAChRs measured with agonist radioligands in rat forebrain are the ␣4␤2 subtype (Whiting and Lindstrom, 1987; Flores et al., 1992; Perry et al., 2002) . Therefore, to help determine the fidelity of the agonist binding sites of the heterologously expressed ␣4␤2 receptor subtype in these cells to their counterpart in native tissues, we compared the K i 35 Ϯ 5 820 Ϯ 120 82 Ϯ 11 2700 Ϯ 700 100 Ϯ 10 Choline 14,000 Ϯ 3000 26,000 Ϯ 4000 49,000 Ϯ 12,000 58,000 Ϯ 11,000 35,000 Ϯ 5000 45,000 Ϯ 11,000 43,000 Ϯ 9000 DH␤E 6200 Ϯ 1200 19,0000 Ϯ 40,000 3800 Ϯ 1300 110,000 Ϯ 10,000 600 Ϯ 70 17,000 Ϯ 4000 130 Ϯ 50 MLA 52,000 Ϯ 19,000 110,000 Ϯ 30,000 1100 Ϯ 300 2200 Ϯ 500 28,000 Ϯ 8000 6400 Ϯ 2200 6600 Ϯ 1500 Mecamylamine Ͼ500,000 Ͼ500,000 Ͼ500,000 Ͼ500,000 Ͼ500,000 Ͼ500,000 Ͼ500,000 values of ligands at these receptors. As shown in Fig. 3 , the K i values of the 10 agonists examined at the ␣4␤2 receptors expressed in the cell line and those in rat forebrain were highly correlated (r Ͼ 0.99). Even more important, however, the best fit line for the correlation was very nearly the line of identity, indicating that not only the rank order of the affinities but also the absolute K i values of these agonists at the binding sites in the two tissues are virtually indistinguishable (see also Table 2 ). These data indicate that the pharmacology of the ␣4␤2 receptor binding sites in these cells accurately reflects the pharmacology of agonists for these sites in forebrain. Interestingly, the affinities of the two competitive antagonists DH␤E and MLA for the receptors in the forebrain and in these cells were not as close as the affinities of agonists. Nevertheless, the relative affinities of the two antagonists were similar for the ␣4␤2 receptors in both rat forebrain and the cells, with the affinity of DH␤E being ϳ50 times higher than that of MLA in both (Table 2) . A similar close correspondence between heterologously expressed ␣3␤2 and ␣3␤4 nAChRs and the native receptors in PC12 cells has been found. Thus, in PC12 cells grown in the presence of nicotine, the pharmacology of the nAChR binding sites labeled by [ 3 H]EB is nearly identical to that in the KX␣3␤2 cells presented here, whereas in PC12 cells grown in the presence of nerve growth factor, the pharmacology of the nAChR binding sites is virtually identical to that of the receptors expressed in the KX␣3␤4 cells (Avila et al., 2003) . Moreover, the potencies of nicotinic agonists to activate channel function measured by 86 Rb ϩ efflux in PC12 cells treated with nerve growth factor and in the KX␣3␤4 cells are nearly identical (Avila et al., 2003) . Taken together, these data indicate that these heterologously expressed nAChRs accurately reflect the pharmacology of native nAChR binding sites.
Regulation of nAChR Subtype Binding Sites by Nicotine. In vivo administration of nicotine increases the density of nAChR binding sites in rodent brain (Marks et al., 1983; Schwartz and Kellar, 1983) , and a similar increase is found in brains from human smokers (Benwell et al., 1988; Breese et al., 1997; Perry et al., 1999) . As a potential model for studying the mechanisms of this unusual effect of nicotinic agonists, several groups have demonstrated that in cells that stably express defined heterologous nAChR subtypes, incubation with nicotine for several hours to several days can increase the density of nAChR binding sites in human ␣4␤2 and ␣3␤2 subtypes (Peng et al., 1994; Gopalakrishnan et al., 1996; Wang et al., 1998) and in the rat ␣3␤4 subtype (Meyer et al., 2001) . To compare the effect of nicotine treatment across the different subtypes and to determine whether carbachol, a quaternary amine agonist that does not readily cross cell membranes, could also affect nAChR binding sites, cells expressing each of the six subtypes were grown in the presence of nicotine (from 0. 
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seen in all subtypes at nicotine concentrations of 2 M or less. However, the extent of the increases varied markedly across the subtypes, and, although all of the increases were greater than what is usually found in brain tissues after in vivo treatment, the largest increases were seen in the three subtypes containing the ␤2 subunit, whereas the smallest increase was seen in the ␣3␤4 subtype. At the highest concentration of nicotine tested, the increases in [ 3 H]EB binding varied from ϳ2.5-fold (␣3␤4 subtype) to ϳ60-fold (␣3␤2 subtype).
Nicotine might increase binding to nAChRs by acting at the agonist binding sites on the extracellular surface, or, because it is lipophilic and readily crosses cell membranes, it might affect nAChRs from inside the cell. Therefore, to begin to examine the question of where agonists act to increase binding sites, [
3 H]EB binding was measured in membranes from cells grown for 5 days in the presence of 200 M carbachol, which does not readily cross cell membranes. Carbachol significantly increased [ 3 H]EB binding at all of the nAChR subtypes; again, the largest increases were seen in the ␤2-containing subtypes (Fig. 5) .
Discussion
Ligand binding measurements at different subunit combinations are an important step in the descriptive pharmacology of the nAChR subtypes and a reasonable start toward developing the pharmacology of their function. Moreover, binding studies can provide essential structure activity information that can lead to the development of new and sub- type-selective drugs, which might have both research and therapeutic utility. In this report, we have presented a comprehensive comparative study describing the pharmacological profiles of the agonist binding sites for six defined nAChR subtypes stably expressed in a mammalian cell line. The functional properties of three of these subtypes have been reported previously (Xiao et al., 1998; Zhang et al., 1999; Meyer et al., 2001; Fitch et al., 2003; Jensen et al., 2003) .
The pharmacology of these binding sites varies substantially across the six subtypes examined here. Even epibatidine and its iodinated analog, which have high affinity for all of the subtypes and are among the least discriminating drugs overall, display 10-to 20-fold differences between the subtypes with the highest and lowest affinity. The rank order of the affinities of the drugs for the binding sites at these six nAChR subtypes agrees well with that found by Luetje and colleagues (Parker et al., 1998) in X. laevis oocytes expressing the same six rat receptors, and even the absolute values in the two expression systems agree reasonably well. Similarly, the affinity of [ 3 H]EB at the three subtypes containing rat ␤4 subunits is in good agreement with that found for these subtypes containing human ␤4 receptors expressed in HEK cells (Stauderman et al., 1998) , and the affinities of nine drugs measured in competition binding at the rat ␣4␤2 receptor (Table 2 ) correlate very highly (r Ͼ 0.99) with their affinities at the human ␣4␤2 receptor (Eaton et al., 2003) .
How well any of these heterologous expression systems represent native receptors is not known with certainty because few native tissues express only one nAChR subtype, which confounds comparisons. However, the very close agreement between the affinities of the 10 agonists at the heterologously expressed defined ␣4␤2 receptors in our cell line and at the receptors in rat forebrain, which expresses predominantly the ␣4␤2 subtype (Whiting and Lindstrom, 1987; Flores et al., 1992; Perry et al., 2002) , indicates that the heterologously expressed receptors accurately represent the binding site pharmacology of agonists at native ␣4␤2 nAChRs. Similarly, previous studies have shown that the binding site pharmacology of the heterologously expressed ␣3␤2 and ␣3␤4 receptors in these cells is nearly identical to that of the predominant native receptors found in PC12 cells grown in the presence of nicotine and nerve growth factor, respectively (Avila et al., 2003) . Taken together, these data indicate that these heterologously expressed nAChRs provide reliable information about the pharmacology of the agonist binding sites of native receptors.
The most discriminating of the drugs examined here were A-85380 and its iodinated analog, I-A-85380, both of which have much higher affinities at nAChR subtypes containing ␤2 subunits than ␤4 subunits. A particularly important comparison is between the affinities of drugs at nAChRs in rat forebrain, where the ␣4␤2 subtype predominates, and at ␣3␤4 receptors, which predominate in peripheral ganglia and are also heavily represented in certain brain areas. All of the agonist drugs examined have higher affinity for ␣4␤2 receptors than for ␣3␤4 receptors, but A-85380 and I-A-85380 were by far the most selective in this regard, with affinity ratios of 310 and 2500, respectively. Nicotine, cytisine, and the competitive antagonist DH␤E also were moderately to highly selective for ␣4␤2 receptors over ␣3␤4 receptors, displaying affinity ratios of ϳ37, 120, and 850, respectively. Interestingly, MLA did not follow this pattern and displayed a higher affinity for ␣3␤4 receptors than for ␣4␤2 receptors.
Drugs that discriminate between subtypes of nAChRs can be very useful in determining the distribution of subtypes in tissues that contain more than one subtype, such as the CNS. For example, relatively low concentrations of cytisine or A-85380 can nearly completely mask all ␣4␤2 nAChRs, whereas leaving most of the receptors containing ␤4 subunits available for binding by radioligands (Marks et al., 1998; Perry et al., 2002) . Moreover, because cytisine, unlike A-85380, has ϳ30-fold lower affinity for ␣3␤2 receptors than for ␣4␤2 receptors, under carefully chosen conditions it can be used to discriminate between these subtypes (Perry et al., 2002) . It should be pointed out, however, that the pharmacology of the nAChRs containing ␣6 subunits is not yet known, and it could be similar to that of one of the other receptor subtypes described here.
In general, the affinities of agonists and of DH␤E were higher at binding sites formed with any one of the ␣ subunits paired with a ␤2 subunit than with a ␤4 subunit. These results are in good agreement with studies of these receptor subtypes expressed in oocytes, which concluded that the ␤ subunit exerts a large influence on the affinities of agonists at nAChR binding sites (Parker et al., 1998) . However, the ␣ subunit also appears to contribute to the pharmacology of the binding sites, although to a lesser extent. In particular, holding the ␤ subunit constant, nicotine and cytisine have a somewhat lower affinity for receptors containing the ␣3 subunit than the ␣2 or ␣4 subunits. In contrast, MLA has a higher affinity for receptors containing ␣3 subunits. Administration of nicotine to rats in vivo increases binding to some, although not all, nAChR subtypes (Flores et al., 1997; Dávila-García et al., 2003) . In the cell lines examined here, exposure to nicotine or carbachol for 5 days increased the number of [ 3 H]EB binding sites of all of the nAChR subtypes, suggesting that an increase in response to agonists is an intrinsic property of the receptor. However, the increases were usually much greater in the subtypes containing ␤2 subunits than in those containing ␤4 subunits (15-to 60-fold increases versus 2-to 10-fold increases).
It should be noted that the ␣4␤2 nAChR, the major subtype increased in rat forebrain by nicotine administration in vivo (Flores et al., 1992) , increased much more in these cells than in brain. Moreover, the ␣3␤4 subtype, which represents one of the major nAChR subtypes in autonomic ganglia (Conroy and Berg, 1995; Mandelzys et al., 1995; Wong et al., 1995; Wang et al., 2002) and in the pineal gland (Hernandez et al., 1999; Perry et al., 2002) , is significantly increased by exposure to even relatively low concentrations of nicotine in these cells; in contrast, administration of nicotine to rats does not increase the nAChRs in the superior cervical ganglia, adrenal gland, or pineal gland (Flores et al., 1997; Dávila-García et al., 2003) . Previous studies suggested that different heterologous expression systems (e.g., oocytes versus mammalian cells) might influence the channel properties of nAChRs (Lewis et al., 1997) , and our data here suggest that the cell type in which nAChRs are expressed might also influence the extent to which nicotine increases the density of the receptor binding sites.
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The increased nAChR binding sites induced by nicotine are not accompanied by increased subunit mRNA in mice (Marks et al., 1992; Pauly et al., 1996) or in cultured cells (Peng et al., 1997; Avila et al., 2003) , which suggests synthesis of new receptor subunits is not required. One way that nicotine could increase the density of nAChRs without altering their synthesis rates is by inhibiting their degradation (Peng et al., 1994) . If this is the case, a very rapid turnover rate of the receptors would predispose them to a large nicotine-induced increase, as is seen in most of these heterologously expressed receptor subtypes. All heterologously expressed nAChRs might display a relatively high intrinsic turnover rate, which could account for the observations of nicotine-induced increases in the different subtypes examined (Peng et al., 1994; Gopalakrishnan et al., 1996; Wang et al., 1998; Meyer et al., 2001) , but the turnover rate of rat receptors expressed in human cells might be even higher, resulting in even greater increases when the cells are exposed to nicotine.
If the concept that the extent of nicotine's effect to increase nAChRs is related to the turnover rate of the receptors is applied to native nAChRs in mammalian tissues, it could help to explain the observations that in rat and mouse brain, administration of nicotine does not increase the presumed same ␣4␤2 subtype equally in all regions (Kellar et al., 1989; Marks et al., 1992; Sanderson et al., 1993) . For example, the same receptor subtype could have much different turnover rates depending on whether it is located on the neuron's cell body, dendrites, or axon terminals. Furthermore, it could link this pharmacological effect of nicotine to intrinsic and extrinsic factors that influence neurons, such as neuronal activity, hormones, or other drugs, that might affect the turnover rate of nAChRs. Thus, there could be a state-dependent aspect to nicotine's effects on receptors.
In conclusion, we developed a library of HEK 293 cells that stably express six different potential nAChR subtypes. Receptor binding studies indicate that some drugs may be useful as discriminators between certain subtypes. Exposure of these cells to nicotine or carbachol for several days increases the density of nAChR binding sites for all of the subtypes studied here. Moreover, the increase in each of the receptor subtypes after exposure to carbachol, which does not readily enter cells, suggests that the agonist-induced increase in nAChRs may be initiated by an action at the cell surface. Taken together, these studies indicate that these cells should be useful models with which to probe the receptor binding site pharmacology and possibly some aspects of the regulation of the receptor density. In addition, the high density of the receptors in these cells may provide enough material for structural and biochemical studies of the subunits and their associations.
